Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). Review uri icon

Overview

abstract

  • Tyrosine kinase inhibitors (TKIs) have emerged as a new frontier of cancer therapy. These agents include inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), BRAF, mitogen‑activated protein kinase kinase (also referred to as MEK), bcr‑abl, c‑KIT, platelet‑derived growth factor (PDGFR), fibroblast growth factor receptor (FGFR), anaplastic lymphoma kinase (ALK) and vascular endothelial growth factor (VEGF). Along with the evolving applications of TKIs, there has been an increased recognition of the breadth of potential cutaneous toxicities to these agents. In this review, we provide an overview of potentially life‑threatening severe cutaneous adverse reactions (SCARs) that may occur during therapy with TKIs. These toxicities include Stevens‑Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP).

publication date

  • December 24, 2020

Research

keywords

  • Drug Eruptions
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases

Identity

PubMed Central ID

  • PMC7859912

Scopus Document Identifier

  • 85100303986

Digital Object Identifier (DOI)

  • 10.3892/or.2020.7911

PubMed ID

  • 33650659

Additional Document Info

volume

  • 45

issue

  • 3